Background
Methods
Number | Median | Range | |
---|---|---|---|
Male/female | 7/5 | ||
Age (years) | 12 | 50.5 | [5–70] |
Charlson comorbidity index | 12 | 2.0 | [2–6] |
ASA physical status classification | 12 | 2 | [1–3] |
Anatomical situation | |||
Primary anatomical single kidney | 6 | ||
Bilateral tumors | 6 | ||
Location of tumor | |||
Central/renal pelvis | 10 | ||
Upper/lower pole | 2 |
Number | Median | Range | |
---|---|---|---|
Surgical results | |||
Perioperative mortality | 0 | ||
Total operative time (min) | 12 | 360 | [270–490] |
Warm ischemia time (min) | 12 | 50 | [25–60] |
Cold ischemia time (min) | 12 | 195 | [160–280] |
Hospital stay (days) | 12 | 29.5 | [18–43] |
Intraoperative complications | 6 | ||
Transfusion | 6 | ||
Postoperative complications (Clavian ≥ 2) | 7 | ||
Postoperative transfusion | 6 cases | ||
Delayed graft function | 2 cases intermitted hemodialysis | ||
Functional outcome | |||
Serum creatinine preoperatively (mg/dl) | 12 | 1.07 | [0.5–1.21] |
Serum creatinine (at discharge) (mg/dl) | 12 | 1.17 | [0.83–4.29] |
Hemodialysis at discharge | 0 | ||
Pathology | |||
Tumor diameter (cm) of renal solid tumors | 7 | 8.25 | [7–12] |
Tumor diameter (cm) of upper urinary tract urothelial carcinoma (UTUC) | 5 | 1.0 | [0.6–3.5] |
Histology | |||
Renal cell carcinoma (RCC) | 5 | ||
UTUC | 5 | ||
Renal metastasis resection | 1 | ||
Nephroblastoma | 1 |
Number | Median | Range | |
---|---|---|---|
Follow-up | |||
Follow-up (months) | 12 | 83.5 | [9–477] |
Patients deceased during follow-up (months) | 6a | – | [9–246] |
Patients lost to follow-up | 1 | After 69 months with graft function | |
Functional outcome and follow-up | |||
Pat. needed hemodialysis at last follow-up | 1 | 105 months after surgery due to nephrectomy for local recurrence at the autotransplanted kidney | |
Cumulative months without hemodialysis on follow-up, or till death with functioning graft | 12 | 1424 months | |
Oncological outcome and follow-up | |||
Recurrence or metastasis | 5 cases | ||
Tumor-related death | 2 cases | ||
RCC progression | 1 case | ||
RCC or UTUC local recurrence | 4 cases | Resection of UTUC in ureter or nephrectomy or partial nephrectomy of autotransplanted kidney | |
Patients on systemic therapy | 1 | Pazopanib for met. RCC | |
Disease-free survival (months) | 48 | [12–72] |